I am a
Home I AM A Search Login

Past Disclosures



The 2024 Global Year will examine what is known about sex and gender differences in pain perception and modulation and address sex-and gender-related disparities in both the research and treatment of pain.

Learn More >

As is the case with many health and scientific membership associations, IASP accepts funds from industry to support our programs. However, pharmaceutical, medical device, and other scientific and health-related companies are not involved in any way in reviewing or determining the scientific content of IASP journals, the World Congress on Pain, or any IASP meetings. Only highly qualified IASP members with significant topical expertise develop and assess our educational materials.

Representatives of these firms may attend the World Congress within the exhibit hall and other public areas of the meeting. Any content presented by these companies at the Congress or any other IASP meeting is clearly labelled to ensure transparency. IASP and these firms follow all applicable local laws.

In addition, IASP maintains a conflict of interest policy regarding endorsements that all association leaders are required to follow. It declares that it is acceptable for organizational leaders to participate in activities with industry-such as speaking roles, advisory board memberships, authors of monographs or papers, consultation-but it must be clear at the time of accepting an invitation that the leader is not representing IASP. To avoid the appearance that the leader is endorsing a product or company on behalf of IASP, all marketing of the activity must omit the leader’s role within IASP.

IASP bylaws state that each director, principal officer, and member of a committee with governing board-delegated powers shall annually sign a statement that affirms that he or she (1) has received a copy of the conflict of interest policy, (2) has read and understands the policy, (3) has agreed to comply with the policy, and (4) understands that the organization is charitable and to maintain its federal tax exemption must engage primarily in activities that accomplish one or more of its tax-exempt purposes. In addition, each of these individuals must provide the additional information requested by the statement.

Following are the procedures the IASP Council has adopted in working with industry:

Who can initiate and secure relationships with industry on behalf of IASP

Any officer, director, member of a committee with governing board-delegated powers, employee, or agent of the organization can initiate contact with a commercial entity on behalf of IASP after first asking the Secretariat to approve the solicitation concept and applicable program or initiative intended to receive funding. Conflicts of interest must be disclosed. Approved persons who initiate contact will turn that relationship over to the Secretariat to confirm funding agreements by means of a contract between IASP and the commercial entity. Contracts will detail the funding to be received, how such support will be disclosed, and explicit benefits to both IASP and the commercial entity. In no event shall any officer, director, member of a committee with governing board-delegated powers, employee, or agent of IASP sign an agreement with such a third party, nor shall such an individual have the authority to sign such an agreement, unless such rights are set out in IASP’s articles of incorporation or bylaws or unless specifically authorized by the IASP Council.

Interactions with industry

Any officer, director, member of a committee with governing board-delegated powers, employee, or agent of the organization who initiates or maintains a relationship with industry on behalf of IASP should do so without self-serving interest. Such an individual will not accept personal gifts, favors, or monetary funds as a result of procuring commercial support originating from these relationships or in violation of any applicable laws.

Identification of programs for commercial support

The Executive Committee and Council will annually identify initiatives and programs for which commercial support is sought. Those items prioritized for industry funding should support IASP’s strategic plan and specifically align with organizational goals identified for the year in which support is solicited.

Guiding principles when securing commercial support

Any commercial entity with which IASP enters into relationship must adhere to IASP’s guiding principles, including but not limited to IASP’s conflict of interest policy. Industry partners must be ethical, appropriate, and professional and must support IASP’s mission to improve pain relief worldwide through research, education, practice, and policy. IASP must maintain independence from industry during the creation and delivery of any educational program and initiative. Programs supported by industry should be free from commercial influence. If there is any commercial influence, such influence must be clearly stated and disclosed and must be cleared by the IASP Executive Committee.

Alignment with industry codes of conduct

Any commercial entity with which IASP enters into a relationship should adhere to both the spirit and the letter of the following industry codes that align with IASP principles: International Federation of Pharmaceutical Manufacturers & Associations Code of Practice, Advanced Medical Technology Association Code of Ethics, and the Pharmaceutical Research and Manufacturers Association Codes and Guidelines.

  • AnaBios
  • Canopy Growth Corp
  • Digitimer, UK
  • Erchonia Lasers Ltd.
  • Grünenthal
  • Lotus Clinical Research
  • Medoc Ltd
  • PCCA Ltd
  • QST.Labs
  • Saluda Medical
  • Somedic SenseLab
  • Ugo Basile SRL
  • Wisepress Medical Bookshop
  • Grünenthal Germany
  • Medoc
  • BioDelivery Sciences
  • Canopy Growth Corporation
  • Vertex Pharmaceuticals, Inc.
  • Jackson Laboratory
  • AusCann Group Holdings LTD
  • Pfizer-Lilly Alliance
  • Novartis Pharma AG
  • Ugo Basile S.R.L.

In 2019, the following companies provided funds for specific programs through grants or support:

  • Mundipharma Pte: Subscriptions to the Professional Educational Resource Center (PERC)
  • Mundipharma Pte: PAIN REPORTS – Developing Countries special issue article publishing fee
  • Teva- Patient Engagement Meeting
  • Teva – Best of WCP day in Mexico in conjunction with the FEDELAT Annual Meeting
  • University of Rochester School: Educational Support for North American Pain School
  • The MAYDAY Fund: Independent Education Grant for the IASP Pain Research Forum/RELIEF
    • American Academy of Pain Medicine
    • American Preclinical Services
    • Amgen
    • AnaBios
    • ANS Biotech
    • Applied VR
    • Artemis Shielding
    • BCI Pharma
    • Bio-Physics Labs
    • BioDelivery Sciences International
    • Biogen
    • Bioseb
    • Boston Scientific
    • Canopy Growth Corporation
    • Cefaly Technologies
    • Clarius Mobile Health
    • Collegium Pharmaceutical, Inc.
    • Current Medical Technologies, Inc.
    • Diros Technology Inc. (DTI)
    • Electromedical Products International
    • Elsevier
    • Equip Medikey BV
    • Fujifilm SonoSite
    • GMMB
    • Grunenthal
    • IMI Pain Care
    • Interactive Forums, Inc.
    • International Myopain Society
    • International Neuromodulation Society (INS)
    • Intercross
    • Karuna VR
    • Kinesio Holding Co.
    • MayDay Fund
    • McGill University (AECRP)
    • Med Val
    • Medoc Ltd
    • Medtronic
    • Metris BV
    • Music Care
    • National Disease Research Interchange
    • NeuroService
    • Nevro Corp
    • NIH
    • OPTP
    • Ouchie
    • Oxford University Press
    • Pfizer Inc.
    • Pfizer Inc. & Eli Lilly and Company
    • Priavoid GmbH
    • Purdue Pharma L.P.
    • Resolve Digital Health
    • Spectra Medical Devices
    • St. Jude Medical
    • Stoelting Co.
    • Sublimed
    • Teva
    • Teva & Regeneron
    • Theranica Bio-Electronics, Ltd
    • Tiger Tail USA
    • Transpharmation Ltd
    • Tufts University (PREP)
    • Ugo Basile
    • University of Southern California
    • University of Sydney
    • University of Maryland
    • UW Health
    • Verified Clinical Trials LLC
    • Vertex Pharmaceuticals Inc.
    • Wellness Consultant LLC
    • Wiley
    • Wolters Kluwers
  • ZT Logistics LLC Mayday Fund: Independent Education Grant for the IASP Pain Research Forum/RELIEF
  • Mundipharma: Independent Education Grant for the IASP African Pain Camp
  • Mundipharma: Independent Education Grant to increase access to IASP’s digital education platform to nonmembers
  • Pfizer: Independent Education Grant for the Extension: Multidisciplinary Pain Clinic Toolkit Project – other regions
  • Pfizer: Independent Education Grant for the South East Asian Pain Education Camp
  • Pfizer: Joint RFP for development of Japanese Pain Education. A Grant Funding Program to individual researchers in Japan.
  • Teva: Independent Education Grant for the IASP Latin American Pain Camp Grunenthal-Grant to support North American Pain School
  • Janssen-Grant to support IASP-ISSP Multidisciplinary Evidence-Based Pain Management Program, a partnership between IASP and the Indian Society for the Study of Pain
  • Mundipharma Pte Limited-Grant to support IASP’s digital platform
  • Pfizer-Grant to support IASP’s digital platform. Grant to support logistics and translation services for “IASP Day” at the Federación Latinoamericana de Asociaciones para el estudio del Dolor. Grant to support an educational tool kit to help establish pain clinics in Indonesia, Vietnam, and Myanmar
  • Teva Pharmaceutical-Grant to support the 2018 Latin America Pain Camp American Preclinical Services
    • ANS Biotech
    • Astellas Pharma Europe Ltd
    • Astra Zeneca
    • Bentham Science
    • BIOSEB
    • Boston Scientific
    • Cefaly Technologies
    • Cosman Medical
    • Daiichi Sankyo HS and US
    • Grunenthal
    • Halyard Health
    • Medoc Ltd
    • Medtronics
    • Metris BV
    • Mundipharma Pte Limited
    • NeuroService
    • Nevro Corp.
    • Ochre Media
    • Osachi Co. (Japan)
    • Pierre-Fabre Australia Pty Ltd
    • Pfizer
    • Purdue Pharma L.P.
    • Spectra Medical Devices
    • Stoelting
    • Teikoku Seiyaki
    • Teva Pharmaceutical
    • Theranica Bio Electronics, Ltd
    • Transpharmation
    • UGO Basile S.r.l.

In 2020, the following companies provided funds for specific programs through grants or support:

  • Nevro Corporation
  • AnaBios
  • AusCann
  • Cellectricon
  • Equip Medikey
  • GlaxoSmithKline
  • Novartis AG
  • Pfizer
  • Teva Pharmaceuticals
  • Transpharmation
  • Ugo Basile
  • Pfizer-Lilly Alliance: Pain Management in Musculoskeletal and Rheumatic Disease: Helping to Bridge Educational Gaps for Better Treatment Outcomes and Improved Function: A Multifaceted Campaign
  • Pfizer Upjohn: Regional and International Pain Management: A Virtual Pain Series Focusing on Educational Gaps in Southeast Asia
  • Rita Allen Foundation: PRF Virtual Correspondents Program
    University of Texas at Dallas: PRF Seminar Series
Share this